Clinical OMICs - Issue 5 - (Page 30)

Clinical OMICs MEETING ROUND-UP July 27-31 August 19-21 Chicago, IL www.aacc.org Connect with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine. Learn about cuttingedge technology with more than 200 new product introductions. Hear vital research about important changes in the field by attending plenary sessions with different perspectives on the future of healthcare, brown bag sessions for intimate and active discussions among participants, and a meet the experts session for intense discussions with plenary speakers and other invited experts. Washington, DC www.nextgenerationdx.com Access to next-generation diagnostics will be gained through creation and management of partnerships in the community around development, commercialization, reimbursement, and regulation. This year's Next Generation Dx Summit will showcase advances in personalized medicine through a program encompassing companion diagnostics, infectious disease, cancer molecular markers, point-of-care, inherited disorders, cell-free DNA, and single-cell sequencing. The event will showcase key components of major players in the diagnostics arena and their successful adoption in the clinic and advancement to the market. August 4-8 September 23-25 Bethesda, MD www.biotrac.com Researchers involved in clinical proteomics face numerous methodological, analytical, and statistical challenges that need to be addressed in order for successful completion of projects. Large-scale biomarker discovery efforts include the coordination of many different disciplines, such as biochemistry, proteomics and mass spectrometry, clinical chemistry, and bioinformatics. In this course, students will be exposed to many of the challenging aspects of biomarker discovery projects, as well as to the numerous analytical platforms that may be employed. Topics being covered include study design and sample collection/storage, sample handling, and quality control and reproducibility in measurements. Boston, MA www.world-cdx.com Maximize your understanding of disease heterogeneity, validation of clinically relevant biomarkers, and co-development and commercialization of drug-CDx combinations. This summit will deliver a multitude of interactive formats, such as one-on-one keynote interviews, live virtual Twitter debates, breakout roundtables, panel discussions, and more. You'll also be able to construct and develop complete biomarker strategies dealing with incorporation of biomarkers into clinical trial design, huge datasets, and patient stratification. The dynamic platform will provide you with extensive opportunities to network with field leaders and colleagues who are tackling challenges similar to those you may be facing. AACC Annual Meeting Clinical Proteomics and Biomarker Discovery Next Generation Dx Summit World CDx Boston City images courtesy of Wikipedia Commons: Chicago, Daniel Schwen; Bethesda, Andrew Bossi; Washington DC, USAF Tech. Sgt. Andy Dunaway; Boston,Henry Han 30 Clinical OMICs June 12, 2014 www.clinicalomics.com http://www.nextgenerationdx.com http://www.aacc.org http://www.biotrac.com http://www.world-cdx.com http://www.clinicalomics.com

Table of Contents for the Digital Edition of Clinical OMICs - Issue 5

Contents

Clinical OMICs - Issue 5

https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue15
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue14
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue13
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue1
https://www.nxtbookmedia.com